45results about How to "Blocking interaction" patented technology

The invention relates to a hybridoma cell strain SZ-125(3D2) with the prevention number of CGMCC NO.2501 and a bi-functional monoclonal antibody capable of anti-human von willbrand factor-A3 secreted by the hybridoma cell strain. The monoclonal antibody is combined with the VWF A3 to block the combination of the VWF A3 and collagen and simultaneously influences the configuration of domain A1, thereby destroying the original domain A1 configuration capable of combining platelet GPIb alpha and achieving the aim of blocking the interaction of the VWF A1 and the GPIb alpha, so that not only combination of the VWF A3 and the collagen is blocked but also the combination of the VWF A1 and the platelet GPIb alpha is blocked. Thus, the monoclonal antibody can be used for preparing anti-artery thrombosis medicine with anti-platelet adhesion activity.

The invention belongs to the technical field of detergents, and in particular relates to an odor-removing and fragrance-retaining agent and a preparation method and application thereof. The present invention combines oxidation-resistant microcapsule essence fragrance beads with coated sodium percarbonate capable of dispelling peculiar smells to obtain an odor-removing and fragrance-retaining agent that can not only dispel peculiar smells on clothes, but also keep fragrance on clothes continuously. The deodorant has the functions of lasting fragrance, cleaning and decontamination, disinfection and sterilization. The present invention inhibits the volatilization of the essence by microencapsulating the essence and the sealing effect of the capsule wall, and blocks the interaction between the essence and other components, so that the essence is more stable during use and storage. Capsule essence has a slow-release effect and can achieve the effect of fragrance retention. Adding microcapsule essence to textiles as a finishing agent can keep the fragrance for more than 12 months, and the fragrance retention effect is obvious.

The invention relates to the technical field of biology, and more specifically relates to a purpose of epirubicin hydrochloride in preparation of an inhibitor for blocking interaction p97 and Npl4. The function of epirubicin hydrochloride which can effectively block the interaction of p97 and Npl4 is firstly found, a RIG-I mediated IFNbeta signal pathway is promoted so as to increase the anti-virus infection capability, so that the treatment effect for virus infection is enhanced, and the epirubicin hydrochloride has clinical and market value.

The invention belongs to the technical field of biological medicine, and relates to a human leukocyte antigen HLA-B*51: 01 gene detection kit. An HLA-B*51: 01 gene can be used as a marker gene for predicting clindamycin-induced drug rash. The invention provides the application of the detection kit to typing of the HLA-B*51: 01 gene in a sample. The application comprises the following steps: extracting DNA from obtained peripheral blood of a patient, and detecting the HLA-B*51: 01 gene by a current method, such as a sequence-specific oligonucleotide probe (PCR-SSO) method. The HLA-B*51: 01 gene detection kit provided by the invention can be applied to screening and sifting of targeted drugs for treating the clindamycin-induced drug rash before the use of clindamycin; screening application can guide clinical drug use so as to reduce incidence of the clindamycin-induced drug rash; selecting application mainly acts on an HLA-B*51: 01 molecule in a targeted manner so as to block interaction between the HLA-B*51: 01 molecule and clindamycin or other metabolites during the drug rash.

The invention discloses the application of the HLA‑A*24:02 allele in detecting the risk of drug eruption caused by metronidazole in humans. The present invention provides the application of a substance for detecting whether a human has an HLA-A*24:02 allele in the preparation of a product for detecting or evaluating the risk of adverse drug reactions in response to metronidazole in humans. Experiments of the present invention prove that the human leukocyte antigen gene—HLA-A*24:02 allele is related to the onset of drug eruption caused by metronidazole. The HLA‑A*24:02 allele can be used as a marker gene to predict the risk of metronidazole-induced drug eruption.

The invention discloses an application of a polypeptide specifically bingd to TRB3 or a derivative of the polypeptide in the preparation of medicines for treating and / or preventing metabolic syndrome. The amino acid sequence of the polypeptide is represented by anyone of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3; and the derivative of the polypeptide is a chimeric peptide formed by connecting the polypeptide with a cell penetrating peptide and / or a medicinal composition formed by cooperating the polypeptide with a medicinal assistant. The polypeptide or the polypeptide derivative can specifically bind to the TRB3 in order to block out interaction between the TRB3 and a P62 protein, and the peptide derivatives Pep2-A1, Pep2-A2 and Pep3-A3 can be used to treat high fat diet induced mouse metabolic syndrome.

The invention discloses application of polypeptide specific-binding TRB3 in treating or preventing abdominal aortic aneurysm. The amino acid sequence of the polypeptide is showed as SEQ ID NO:1. The polypeptide derivative is a chimeric peptide formed by the polypeptide connecting with a cell penetrating peptide or a dosage form formed by the polypeptide coordinated with a drug excipient. The polypeptide is screened by the surface plasma resonance (Biacore) method, and can specifically bind to TRB3 and blockade the combination of TRB3 and P62 protein. Meanwhile, the polypeptide derivative Pep2-A2 can treat the mice abdominal aortic aneurysm by knocking-out ApoE inducted by angiotensin II. Thus, the polypeptide and the polypeptide derivative can be used as a novel inhibitor for TRB3, and can be used in exploiting vaccine or medicament for inhibiting abdominal aortic aneurysm.